Core Viewpoint - Tronox Holdings plc (NYSE: TROX) is facing a class action lawsuit due to allegations of misleading statements regarding its financial performance and demand forecasting for its products, leading to a significant drop in stock price [1][2]. Summary by Sections Allegations - The complaint claims that Tronox provided overly positive statements while concealing material adverse facts about its commercial division and demand forecasting capabilities [1]. - Despite ambitious long-term projections, Tronox's sales continued to decline, and costs increased, which ultimately affected revenue projections [1]. - On July 30, 2025, Tronox reported a significant reduction in TiO2 sales, attributing the decline to a weaker coatings season and increased competition [1]. Financial Impact - Following the announcement of poor financial results, Tronox revised its 2025 financial outlook, lowering full-year revenue guidance and cutting its dividend by 60% [1]. - The stock price plummeted from $5.14 per share on July 30, 2025, to $3.19 per share on July 31, 2025, marking a decline of approximately 38% in one day [1]. Next Steps for Shareholders - Shareholders who purchased shares during the specified class period are encouraged to register for the class action by November 3, 2025, to potentially become lead plaintiffs [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [2].

NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of KinderCare Learning Companies, Inc. (NYSE: KLC) pursuant and/or traceable to the registration statement issued in connection with KinderCare’s October 2024 initial public offering (the “IPO”), of the important October 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased KinderCare common stock you may be entitled to compensation without payment of any out of pocke ...

Accessibility StatementSkip Navigation NEW YORK, Oct. 2, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) resulting from allegations that MoonLake may have issued materially misleading business information to the investing public. So What: If you purchased MoonLake securities you may be entitled to compensation without payment of any out of pocket fees or c ...

Core Viewpoint - A corrected notice has been issued regarding the deadline for investors to seek appointment as Lead Plaintiff in a class action lawsuit against Charter Communications, with the new deadline set for October 14, 2025 [1][3]. Group 1: Class Action Details - The class action, titled Sandoval v. Communications, Inc., is filed on behalf of individuals who purchased or acquired Charter common stock or traded relevant options between July 26, 2024, and July 24, 2025 [2]. - The lawsuit alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act and SEC Rule 10b-5, claiming that the defendants failed to disclose material adverse facts about the company's operations and outlook [2]. Group 2: Allegations Against Charter - The complaint asserts that the defendants made misleading statements regarding the impact of the FCC's Affordable Connectivity Program (ACP) ending, which affected internet customer declines and revenue [5]. - It is claimed that Charter's management did not adequately address the consequences of the ACP ending, leading to greater risks to business plans and earnings growth than reported [5]. Group 3: Financial Performance and Market Reaction - Charter reported an EBITDA of $5.7 billion for Q2 2025, reflecting a 0.5% year-over-year growth, but this was largely due to a one-time benefit of $45 million, which, if excluded, would have resulted in a 2.4% miss against consensus estimates and a 0.3% decline year-over-year [6]. - The company experienced a loss of 117,000 internet customers in Q2 2025, nearly double the loss of 66,000 in the previous quarter and an increase from a loss of 99,000 customers in Q2 2024 [7]. - Following the financial results announcement, Charter's stock price fell by $70.25 per share, or 18.4%, closing at $309.75 on July 25, 2025 [7].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased PubMatic, Inc. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from February 27, 2025, to August 11, 2025, and the lead plaintiff deadline is October 20, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [2][5]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3]. - The firm has achieved significant settlements in the past, including the largest securities class action settlement against a Chinese company at the time [3]. - In 2019, Rosen Law Firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3]. Group 3: Case Allegations - The lawsuit alleges that during the class period, PubMatic made false and misleading statements regarding its business operations [4]. - Key issues include a major demand side platform buyer shifting clients to a new platform, leading to reduced ad spend and revenue for PubMatic [4]. - The misleading statements resulted in investor damages when the true situation was revealed [4].

Sep 30, 2025 10:35 AM Eastern Daylight Time Share FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo To Contact Him Directly To Discuss Their Options If you suffered losses in Novo between May 7, 2025, to July 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983- ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Rezolve AI plc due to allegations of materially misleading business information issued by the company [1] Group 1 - The investigation is focused on the potential impact of misleading information on investors [1] - Shareholders who purchased Rezolve securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]

Core Viewpoint - A lawsuit has been filed against Lineage, Inc. and its senior executives for potential violations of federal securities laws related to its IPO and subsequent financial performance [1][2]. Group 1: Lawsuit Details - Investors have until September 30, 2025, to request to lead the case, which is based on claims under Sections 11 and 15 of the Securities Act of 1933 [2]. - The lawsuit is pending in the U.S. District Court for the Eastern District of Michigan, specifically titled City of St. Clair Shores Police and Fire Retirement System v. Lineage, Inc., et al. [2]. Group 2: Company Overview - Lineage, Inc. operates as a cold storage-focused real estate investment trust (REIT), owning and managing temperature-controlled storage facilities for perishable products [3]. Group 3: Allegations and Financial Performance - The IPO documents claimed strong cash flows due to consistent cold chain demand, suggesting resilience during economic stress, while the reality indicated a downturn as customers destocked excess inventory from the pandemic [4]. - Following the IPO at $78 per share, Lineage's stock price has significantly declined to around $40 per share, approximately 50% of its initial value [5].

Core Points - Faruqi & Faruqi, LLP is investigating potential claims against Sable Offshore Corp. (NYSE: SOC) [1] - Investors are reminded of the September 26, 2025 deadline to seek the role of lead plaintiff in a federal securities class action filed against the Company [1] - Faruqi & Faruqi is a prominent national securities law firm with offices in New York, Pennsylvania, California, and Georgia [1]

Core Viewpoint - A class action lawsuit has been filed against Cytokinetics, Inc. for allegedly misleading investors regarding the timeline for the New Drug Application (NDA) submission and approval process for aficamten, potentially causing financial damages to investors [1][4]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of purchasers of Cytokinetics common stock between December 27, 2023, and May 6, 2025 [1]. - Defendants allegedly made false statements about the expected FDA approval for aficamten, claiming it would occur in the second half of 2025, while failing to disclose risks related to the submission of a Risk Evaluation and Mitigation Strategy (REMS) [4]. Group 2: Investor Information - Investors who purchased Cytokinetics stock during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][5]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [3].